Occlutech receives the CE mark for its ventricle septal defect closure device

526

Occlutech now has CE mark approval for its muscular ventricle septal defect (mVSD) closure device—is a specifically designed implant indicated for the minimally invasive closure of muscular ventricle septal defects. The device consists of a flexible nitinol wire mesh with “shape-memory” properties.

According to a press release, Occlutech´s proprietary technology allows for the creation of products with unique properties regarding flexibility and adaptability. The implant will be available in different configurations, multiple sizes, and can accommodate a broad range of defects. The Occlutech mVSD implant allows fast, atraumatic, minimally invasive closure of these defects. Ventricle septal defect closure using implantable devices is an alternative to open heart surgery.


Tor Peters, chief executive officer of Occlutech Group, comments: “We are extremely pleased to be able to provide patients and cardiologists with this innovative product and expect our VSD occluder to significantly add and improve therapy options for this patient population.”